Pre-revenue biotech with no earnings surprise — stock movement will depend on clinical data readouts (NOVA-2 H2 2027, ILLUMINATE-1 Q1 2028). Monitor enrollment updates and any early efficacy signals. The $100M financing removes near-term dilution risk.
Price Chart
Executive Summary
LB Pharmaceuticals reported Q1 2026 EPS of -$0.67, in line with consensus of -$0.67, and a net loss of $19.1M vs $5.3M a year ago. The company initiated pivotal Phase 3 NOVA-2 trial in schizophrenia and Phase 2 ILLUMINATE-1 in bipolar depression, with a $100M private placement extending cash runway into Q2 2029. The stock is unlikely to move materially on this quarter's numbers given the pre-revenue stage, but the clinical pipeline progress and strong cash position support the positive sentiment.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.67 vs consensus -$0.67 (in line)
- Net loss $19.1M vs $5.3M in Q1 2025
- Cash, cash equivalents and marketable securities $365.6M as of March 31, 2026
- Initiated pivotal Phase 3 NOVA-2 trial in schizophrenia (topline data H2 2027)
- Initiated Phase 2 ILLUMINATE-1 trial in bipolar depression (topline data Q1 2028)
- Completed $100M private placement in February 2026, net proceeds ~$93.8M
- Cash runway expected into Q2 2029
- Plans to initiate Phase 2 trial in adjunctive MDD in early 2027
Financial Impact
Net loss increased to $19.1M from $5.3M YoY; R&D spend rose to $14.6M from $3.4M; cash position $365.6M provides ~3-year runway
Risk Factors
- Clinical trial failure in NOVA-2 or ILLUMINATE-1
- Regulatory delays or safety issues
- Cash burn rate accelerating beyond current runway projections
- Competition from existing antipsychotics and other late-stage candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.50 (+13.54%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.50 (−15.29%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $39.50 (−8.22%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.50 (−16.88%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $39.50 (−12.86%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $39.50 (−12.86%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.50 (+1.28%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.50 (+10.21%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.50 (+10.21%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.50 (+38.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers